干扰素调节因子 4 在急性淋巴细胞白血病相关性结肠炎的发展过程中发挥关键作用

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-12-27 DOI:10.1080/2162402x.2023.2296712

Jochen T. Frueh, Julia Campe, Daniele Yumi Sunaga-Franze, Nikita A. Verheyden, Sakhila Ghimire, Elisabeth Meedt, Denise Haslinger, Sabine Harenkamp, Daniel Staudenraus, Sascha Sauer, Andreas Kreft, Ralf Schubert, Michael Lohoff, Andreas Krueger, Halvard Bonig, Andreas G. Chiocchetti, Robert Zeiser, Ernst Holler, Evelyn Ullrich

{"title":"干扰素调节因子 4 在急性淋巴细胞白血病相关性结肠炎的发展过程中发挥关键作用","authors":"Jochen T. Frueh, Julia Campe, Daniele Yumi Sunaga-Franze, Nikita A. Verheyden, Sakhila Ghimire, Elisabeth Meedt, Denise Haslinger, Sabine Harenkamp, Daniel Staudenraus, Sascha Sauer, Andreas Kreft, Ralf Schubert, Michael Lohoff, Andreas Krueger, Halvard Bonig, Andreas G. Chiocchetti, Robert Zeiser, Ernst Holler, Evelyn Ullrich","doi":"10.1080/2162402x.2023.2296712","DOIUrl":null,"url":null,"abstract":"Interferon regulatory factor 4 (IRF4) is a master transcription factor that regulates T helper cell (Th) differentiation. It interacts with the Basic leucine zipper transcription factor, ATF-like (...","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":"38 1","pages":""},"PeriodicalIF":7.2000,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis\",\"authors\":\"Jochen T. Frueh, Julia Campe, Daniele Yumi Sunaga-Franze, Nikita A. Verheyden, Sakhila Ghimire, Elisabeth Meedt, Denise Haslinger, Sabine Harenkamp, Daniel Staudenraus, Sascha Sauer, Andreas Kreft, Ralf Schubert, Michael Lohoff, Andreas Krueger, Halvard Bonig, Andreas G. Chiocchetti, Robert Zeiser, Ernst Holler, Evelyn Ullrich\",\"doi\":\"10.1080/2162402x.2023.2296712\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Interferon regulatory factor 4 (IRF4) is a master transcription factor that regulates T helper cell (Th) differentiation. It interacts with the Basic leucine zipper transcription factor, ATF-like (...\",\"PeriodicalId\":19683,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2023-12-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402x.2023.2296712\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402x.2023.2296712","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

干扰素调节因子 4（IRF4）是一种调节 T 辅助细胞（Th）分化的主转录因子。它与基本亮氨酸拉链转录因子、类 ATF（...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Interferon regulatory factor 4 plays a pivotal role in the development of aGVHD-associated colitis

Interferon regulatory factor 4 (IRF4) is a master transcription factor that regulates T helper cell (Th) differentiation. It interacts with the Basic leucine zipper transcription factor, ATF-like (...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.